Immunogenicity assay of the Leishmune® vaccine against canine visceral leishmaniasis in Brazil

Vaccine

Volumn 26, Issue 39, 2008, Pages 4991-4997

  Borja Cabrera, G P ^a   Santos, F N ^a   Bauer, F S ^a   Parra, L E ^b   Menz, I ^b   Morgado, A A ^c   Soares, I S ^c   Batista, L M M ^d   Palatnik de Sousa, C B ^a  

^a FEDERAL UNIVERSITY OF RIO DE JANEIRO   (Brazil)

^b Fort Dodge Saúde Animal Ltda 1   (Brazil)

^c CENTRO DE CONTROLE DE ZOONOSES   (Brazil)

^d Centro de Controle de Zoonoses   (Brazil)

Author keywords

Canine visceral leishmaniasis; FML saponin vaccine; Kala azar; Leishmune ; QS21 saponin; Quillaja saponaria; Zoonotic visceral leishmaniasis

Indexed keywords

COMPLEMENT COMPONENT C3D RECEPTOR; LEISHMANIA VACCINE; LEISHMUNE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; BRAZIL; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CONTROLLED STUDY; DELAYED HYPERSENSITIVITY; DOG DISEASE; DRUG EFFICACY; IMMUNOGENICITY; LEISHMANIASIS; NONHUMAN; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; VISCERAL LEISHMANIASIS;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; ANTIGENS, PROTOZOAN; BRAZIL; DOG DISEASES; DOGS; FLOW CYTOMETRY; HYPERSENSITIVITY, DELAYED; LEISHMANIA DONOVANI; LEISHMANIASIS VACCINES; LEISHMANIASIS, VISCERAL; LEUKOCYTES, MONONUCLEAR; SAPONINS;

EID: 50849103323     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2008.07.029     Document Type: Article

References (56)

1. http://www.who.int/vaccine_research/diseases/soa_parasitic/en/index3.htm l
2. World Health Organization-TDR. The TDR fifteenth programme report. Research Progress 1999-2000. New and Improved Tools 2003. www.who.int/tdr/research/progress 9900/tools/vdr.html.
3. Tesh R. Control of zoonotic visceral leishmaniasis. Is it time to change strategies?. Am J Trop Med Hyg 52 (1995) 287-292
4. Dye C. The logic of visceral leishmaniasis control. Am J Trop Med Hyg 55 (1996) 125-130
5. Khalil E.A.G., El Hassan A.M., Zijlstra E.E., Mukhter M.M., Ghalib H.W., Musa B., et al. Autoclaved Leishmania major vaccine for prevention of visceral leishmaniasis: a randomised, doubled-blind, BCG-controlled trial in Sudan. Lancet 356 (2000) 1565-1569
6. Mohebali M., Khamesipour A., Mobedi I., Zarei Z., and Fesharki R.H. Double-blind randomized efficacy field trial of alum precipitated autoclaved Leishmania major vaccine mixed with BCG against canine visceral leishmaniasis in Meshkin-Shahr district. I R Iran Vaccine 22 (2004) 4097-4100
7. Genaro O., Pinto J.A., Da Costa C.A., França-Silva J.C., Costa R.T., Silva J.C., et al. Phase III randomized double blind clinical trial on the efficacy of a vaccine against canine visceral leishmaniasis in urban area of Montes Claros, MG, Brazil. Mem Ins Osw Cruz 91 (1996) 116
8. Lemesre J.L., Holzmuller P., Cavaleyra M., Gonçalves R.B., Hottin G., and Papierok G. Protection against experimental visceral leishmaniasis infection in dogs immunized with purified excreted secreted antigens of Leishmania infantum promastigotes. Vaccine 23 (2005) 2825-2840
9. Fujiwara R.T., Vale A.M., Franca da Silva J.C., da Costa R.T., Quetz Jda S., Martins Filho A.O., et al. Immunogenicity in dogs of three recombinant antigens (TSA, LeIF and LmSTI1) potential vaccine candidates for canine visceral leishmaniasis. Vet Res 36 (2005) 827-838
10. Moreno J., Nieto J., Masina S., Cañavate C., Cruz I., Chicharro C., et al. Immunization with H1, HASPB1 and MML Leishmania proteins in a vaccine trial against experimental canine leishmaniasis. Vaccine 25 (2007) 5290-5300
11. Gradoni L., Foglia Manzillo V., Pagano A., Piantedosi D., De Luna R., et al. Failure of a multi-subunit recombinant leishmanial vaccine (MML) to protect dogs from Leishmania infantum infection and to prevent disease progression in infected animals. Vaccine 23 (2005) 5245-5251
12. Rafati S., Nakhaee A., Taheri T., Taslimi Y., Darabi H., Eravani D., et al. Protective vaccination against canine visceral leishmaniasis using a combination of DNA and protein immunization with cysteine proteinases type I and type II of L. infantum. Vaccine 23 (2005) 3716-3725
13. Rodríguez-Cortés A., Ojeda A., López-Fuertes L., Timón M., Atlet L., Solano-Gallego L., et al. Vaccination with plasmid DNA encoding KMP11, TRYP, LACK, and GP63 does not protect dogs against Leishmania infantum experimental challenge. Vaccine 25 (2007) 7962-7971
14. Ramiro M.J., Zárate J.J., Hanke T., Rodriguez D., Rodriguez J.R., Esteban M., et al. Protection in dogs against visceral leishmaniasis caused by Leishmania infantum is achieved by immunization with a heterologous prime-boost regime using DNA vaccine and vaccinia recombinant vectors expressing LACK. Vaccine 21 (2003) 2474-2484
15. Borja Cabrera G.P., Santos F.N., Miyashiro L.M., Santos F.B., and Palatnik de Sousa CB S. Vaccine congress on nucleoside hydrolase DNA vaccine against visceral leishmaniasis. vol. 1. Celebrating 25 years of publication. The Netherlands, December 9-11 (2007) pp. 167
16. Palatnik-de-Sousa C.B. Vaccines for leishmaniasis in the fore coming 25 years. Review. Vaccine 26 (2008) 1709-1724
17. da Silva V.O., Borja-Cabrera G.P., Correia Pontes N.N., Paraguai de Souza E., Luz K.G., Palatnik M., et al. A Phase III trial of efficacy of the FML-vaccine against canine kala-azar in an endemic area of Brazil (São Gonçalo do Amarante, RN). Vaccine 19 (2001) 1068-1081
18. Borja-Cabrera G.P., Correia Pontes N.N., da Silva V.O., Paraguai de Souza E., Santos W.R., Gomes E.M., et al. Long lasting protection against canine kala-azar using the FML-QuilA saponin vaccine in an endemic area of Brazil (São Gonçalo do Amarante). Vaccine 20 (2002) 3277-3284
19. Lemesre J.L., Holzmuller P., Gonçalves R.B., Bourdoiseau G., Hugnet C., Cavaleyra M., et al. Long-lasting protection against canine visceral leishmaniasis using the LiESAp-MDP vaccine in endemic areas of France: double-blind randomised efficacy field trial. Vaccine 25 (2007) 4223-4234
20. Palatnik C.B., Borojevic R., Previato J.O., and Mendonça-Previato L. Inhibition of Leishmania donovani promastigote internalization into murine macrophages by chemically defined parasite glycoconjugate. Infect Immun 57 (1989) 754-763
21. Palatnik de Sousa C.B., Gomes E.M., Paraguai de Souza E., Luz K., Palatnik M., and Borojevic R. Leishmania donovani: titration of antibodies to the Fucose Mannose Ligand as an aid in diagnosis and prognosis of Visceral Leishmaniasis. Trans Roy Soc Trop Med Hyg 89 (1995) 390-393
22. Borja Cabrera G.P., da Silva V.O., da Costa R.T., Barbosa Reis A., Mayrink W., Genaro O., et al. The FML-ELISA assay in diagnosis and prognosis of canine visceral leishmaniasis. Am J Trop Med 6 (1999) 296-301
23. ® vaccine blocks the transmission of canine visceral leishmaniasis. Absence of Leishmania parasites in blood, skin and lymph nodes of vaccinated exposed dogs. Vaccine 23 (2005) 4805-4810
24. Borja-Cabrera GP. PhD Thesis. Análise do potencial diagnóstico, prognóstico e imunoprotetor do antígeno FML (Ligante de Fucose Manose) de Leishmania (L.) donovani, no calazar canino experimental e de área endêmica. Universidade Federal Fluminense; 2000. pp. 81-98.
25. Santos W.R., de Lima V.M.F., Paraguai de Souza E., Bernardo R.R., Palatnik M., and Palatnik de Sousa C.B. Saponins, IL12 and BCG adjuvant in the FML-vaccine formulation against murine visceral leishmaniasis. Vaccine 21 (2002) 30-43
26. Palatnik de Sousa C.B., Paraguai de Sousa E., Gomes E.M., and Borojevic R. The FML vaccine (fucose-manosse ligand) protects hamsters from experimental kala-azar. Ciência e Cultura (J Braz Assoc Adv Sci) 46 (1994) 290-296
27. Santos W.R., Aguiar I.A., Paraguai de Souza E., de Lima V.F.M., Palatnik M., and Palatnik-de-Sousa C.B. Immunotherapy against murine experimental visceral leishmaniasis with the FML-vaccine. Vaccine 21 (2003) 4668-4676
28. Borja-Cabrera G.P., Cruz Mendes A., Paraguai de Souza W., Okada L.Y.H., Trivellato F.A.A., Kawasaki J.K.A., et al. Effective immunotherapy against canine visceral leishmaniasis with the FML-vaccine. Vaccine 22 (2004) 2234-2243
29. UNDP/World Bank/WHO Special Programme for Research and Training in Tropical Diseases (TDR). Guidelines for the evaluation of Plasmodium falciparum vaccines in populations exposed to natural infections. TDR/MAL/VAC/97. World Health Organization, Geneva, Switzerland.
30. ®) against canine visceral leishmaniasis: a transmission blocking vaccine. Vaccine 24 (2006) 2423-2431
31. Santos F.N., Borja-Cabrera G.P., Miyashiro L.M., Grechi J., Reis A.B., Moreira M.A.B., et al. Immunotherapy against experimental canine visceral leishmaniasis with the saponin enriched-Leishmune® vaccine. Vaccine 25 (2007) 6176-6190
32. ® vaccine against canine visceral leishmaniasis in Brazil. Vaccine 25 (2007) 2180-2186
33. Ministério da Saúde-SINAN-Secretaria de Vigilância em Saúde. Manual de Vigilância e Controle da Leishmaniose Visceral. Editora Ministério da Saúde. Brasília-DF; 2003. 120 pp.
34. Palatnik-de-Sousa C.B., Melo L.M.B., Borja-Cabrera G.P., Palatnik M., and Lavor C.C. Improving methods for epidemiological control of canine visceral leishmaniasis based on a mathematical model. Impact on the incidence of the canine and human disease. Ann Braz Acad Sci 76 (2004) 583-593
35. Prefeitura de Belo Horizonte/Portal Internet. Saúde, leishmaniose. http://portal1.pbh.gov.br.
36. Oliveira-Freitas E., Casas C.P., Borja-Cabrera G.P., Santos F.N., Nico D., Souza L.O.P., et al. Acylated and deacylated saponins of Quillaja saponaria mixture as adjuvants for the FML-vaccine against visceral leishmaniasis. Vaccine 24 (2006) 3909-3920
37. Marciani D.J. Vaccine adjuvants: role and mechanisms of action in vaccine immunogenicity. Drug Discov Today 8 (2003) 934-943
38. Silva B.P., Soares J.B.R.C., Paraguai de Souza E., Palatnik M., and Palatnik de Sousa C.B. Pulcherrima saponin, from the leaves of Calliandra pulcherrima, as adjuvant for visceral leishmaniasis. Vaccine 23 (2005) 1061-1071
39. Rodrigues M.M., Boscardin S.B., Vasconcelos J.R., Hiyane M.I., Salay G., and Soares I.S. Importance of CD8 T cell-mediated immune response during intracellular parasitic infections and its implications for the development of effective vaccines. Ann Acad Bras Cienc 75 (2003) 443-468
40. Belkaid Y., Von Stebut E., Mendez S., Lira R., Caler E., Bertholet S., et al. CD8+ T cells are required for primary immunity in C57BL/6 mice following low-dose, intradermal challenge with Leishmania major. J Immunol 168 (2002) 3992-4000
41. De Luca P.M., Mayrink W., Alves C.R., Coutinho S.G., Oliveira M.P., Bertho A.L., et al. Evaluation of the stability and immunogenicity of autoclaved and nonautoclaved preparations of a vaccine against American tegumentary leishmaniasis. Vaccine 17 (1999) 1179-1185
42. Bottrel R.L., Dutra W.O., Martins F.A., Gontijo B., Carvalho E., Barral-Netto M., et al. Flow cytometric determination of cellular sources and frequencies of key cytokine-producing lymphocytes directed against recombinant LACK and soluble Leishmania antigen in human cutaneous leishmaniasis. Infect Immun 69 (2001) 3232-3239
43. Pompeu M.M., Brodskyn C., Teixeira M.J., Clarêncio J., Van Weyenberg J., Coelho I.C., et al. Differences in gamma interferon production in vitro predict the pace of the in vivo response to Leishmania amazonensis in healthy volunteers. Infect Immun 69 (2001) 7453-7460
44. Reis A.B., Teixeira-Carvalho A., Giunchetti R.C., Guerra L.L., Carvalho M.G., Mayrink W., et al. Phenotypic features of circulating leucocytes as immunological markers for clinical status and bone marrow parasite density in dogs naturally infected by Leishmania chagasi. Clin Exp Immunol 146 (2006) 303-311
45. Guarga J.L., Moreno J., Lucientes J., Gracia M.J., Peribáñez M.A., Alvar J., et al. Canine leishmaniasis transmission: higher infectivity amongst naturally infected dogs to sand flies is associated with lower proportions of T helper cells. Res Vet Sci 69 (2000) 249-253
46. Araújo M.S., de Andrade R.A., Vianna L.R., Mayrink W., Reis A.B., Sathler-Avelar R., et al. Despite Leishvaccine and Leishmune trigger distinct immune profiles, their ability to activate phagocytes and CD8+ T-cells support their high-quality immunogenic potential against canine visceral leishmaniasis. Vaccine 26 (2008) 2211-2224
47. Giunchetti R.C., Corrêa-Oliveira R., Martins-Filho O.A., Teixeira-Carvalho A., Roatt B.M., de Oliveira Aguiar-Soares R.D., et al. Immunogenicity of a killed Leishmania vaccine with saponin adjuvant in dogs. Vaccine 25 (2007) 7674-7686
48. Bourdoiseau G., Bonnefont C., Magnol J.P., Saint-André I., and Chabanne L. Lymphocyte subset abnormalities in canine leishmaniasis. Vet Immunol Immunopathol 56 (1997) 345-351
49. Moreno J., Nieto J., Chamizo C., González F., Blanco F., Barker D.C., et al. The immune response and PBMC subsets in canine visceral leishmaniasis before, and after, chemotherapy. Vet Immunol Immunopathol 71 (1999) 181-195
50. Guarga J.L., Moreno J., Lucientes J., Gracia M.J., Peribáñez M.A., and Castillo J.A. Evaluation of a specific immunochemotherapy for the treatment of canine visceral leishmaniasis. Vet Immunol Immunopathol 88 (2002) 13-20
51. Keenan C.M., Hendricks L.D., Lightner L., Webster H.K., and Johnson A.J. Visceral leishmaniasis in the German shepherd dog. I. Infection, clinical disease, and clinical pathology. Vet Pathol 21 (1984) 74-79
52. Mendes C.O., Paraguai de Souza E., Borja-Cabrera G.P., Melo Batista L.M., Santos M.A., Parra L.E., et al. IgG1/IgG2 antibody dichotomy in sera of vaccinated or naturally infected dogs with visceral leishmaniasis. Vaccine 21 (2003) 2589-2597
53. Deplazes P., Smith N.C., Arnold P., Lutz H., and Eckert J. Specific IgG1 and IgG2 antibody responses of dogs to Leishmania infantum and other parasites. Parasite Immunol 17 (1995) 451-458
54. Nieto C.G., Garcia Alonso M., Requena J.M., Miron C., Soto M., Alonso C., et al. Analysis of the humoral response against total and recombinant antigens of Leishmania infantum: correlation with disease progression in canine experimental leishmaniasis. Vet Immunol Immunopathol 67 (1999) 117-130
55. Solano-Gallego L., Riera C., Roura X., Inieste L., Gallego M., Valladares J.E., et al. Leishmania infantum-specific IgG, IgG1 and IgG2 antibody responses in healthy and ill dogs from endemic areas. Evolution in the course of infection and after treatment. Vet Parasitol 96 (2001) 265-276
56. Courtenay O., Quinnell R.J., Garcez L.M., Shaw J.J., and Dye C. Infectiousness in a Cohort of Brazilian dogs: why culling fails to control visceral leishmaniasis in areas of high transmission. J Inf Dis 186 (2002) 1314-1320